Drug Type Degrader-antibody conjugates |
Synonyms FFT 135, FFT135 |
Target |
Action degraders |
Mechanism EF-1A degraders(HBS1 like translational GTPase degraders), GSPT1 degraders(G1 to S phase transition 1 degraders), GSPT2 degraders(G1 to S phase transition 2 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | United States | 10 Jan 2024 | |
| Hepatocellular Carcinoma | Preclinical | United States | 10 Jan 2024 | |
| Stomach Cancer | Preclinical | United States | 10 Jan 2024 |






